Can Juno Therapeutics Outmaneuver Its CAR-T Competitors?
Novartis(NYSE: NVS) filed for Food and Drug Administration (FDA) approval of its chimeric antigen receptor T-cell therapy (CAR-T), Kymriah, in late-stage diffuse large B-cell lymphoma (DLBCL) yesterday. If approved, Kymriah will join Gilead Sciences' (NASDAQ: GILD) Yescarta in enjoying early mover advantages over Juno Therapeutics' (NASDAQ: JUNO) JCAR017, which is on pace to get filed for approval in DLBCL next year.
Novartis and Gilead Sciences could end up crowding Juno Therapeutics out of this important market, but JCAR017 can still become a blockbuster if it puts up best-in-class safety in its trials.
IMAGE SOURCE: GETTY IMAGES.
Source: Fool.com
Gilead Sciences Inc Aktie
117,54 €
-0,34 %
Absolute Beliebtheit: Gilead Sciences Inc hat nur Buy-Einschätzungen.
Das Kursziel von 128 € für Gilead Sciences Inc weist auf eine leichte Verbesserung gegenüber dem aktuellen Kurs von 117.54 € hin.
